Skip to main content

Advertisement

SpringerLink
Log in

Corticosteroid switch after progression on abiraterone acetate plus prednisone

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone.

Materials and Methods

The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option.

Results

A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223.

Conclusion

Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA Cancer J Clin. 68:7–30

    Article  Google Scholar 

  2. Crawford ED, Petrylak D, Sartor O (2017) Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 35S:S1–S13

    Article  Google Scholar 

  3. de Bono JS et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005

    Article  Google Scholar 

  4. Ryan CJ et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148

    Article  CAS  Google Scholar 

  5. Attard G, Reid AH, Olmos D et al (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937–4940

    Article  CAS  Google Scholar 

  6. Dizdar O (2015) Is dexamethasone a better partner for abiraterone than prednisolone? Oncologist 20(5):e13

    Article  Google Scholar 

  7. Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. (Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365)

    Article  CAS  Google Scholar 

  8. Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160.

    Article  CAS  Google Scholar 

  9. Roviello G, Sigala S, Danesi R et al (2016) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol 101:12–20

    Article  Google Scholar 

  10. Eichholz A, Ferraldeschi R, Attard G et al (2012) Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 360:68–75

    Article  CAS  Google Scholar 

  11. Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ et al (2001) Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 7:11–15

  12. Crona DJ, Whang YE (2017) Androgen receptor‑dependent and independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel) 9: pii: E67

  13. Arora VK, Schenkein E, Murali R et al (2013) Glucocorticoid receptor confers resistance to antiandrogens bybypassing androgen receptor blockade. Cell 155:1309–1322

    Article  CAS  Google Scholar 

  14. Lan NC, Graham B, Bartter FC et al (1982) Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J Clin Endocrinol Metab 54:332–342

    Article  CAS  Google Scholar 

  15. Dovio A, Sartori ML, De Francia S et al (2009) Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. J Steroid Biochem Mol Biol 116:29–36

    Article  CAS  Google Scholar 

  16. Leach DA, Powell SM, Bevan CL (2016) Women in cancer thematic review: new roles for nuclear receptors in prostate cancer. Endocr Relat Cancer 23:T85–T108

    Article  CAS  Google Scholar 

  17. Taplin ME, Bubley GJ, Shuster TD et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398

    Article  CAS  Google Scholar 

  18. Zhao XY, Malloy PJ, Krishnan AV et al (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703–706

    Article  CAS  Google Scholar 

  19. Richards J, Lim AC, Hay CW et al (2012) Interactions of abiraterone, eplerenone, and prednisolone with wild‑type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72: 2176‑2182

  20. Nishimura K, Nonomura N, Satoh E et al (2001) Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93:1739–1746

    Article  CAS  Google Scholar 

  21. Lam JS, Leppert JT, Vemulapalli SN et al (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175:27–34

    Article  CAS  Google Scholar 

  22. Yano A, Fujii Y, Iwai A et al (2006) Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12:3003–3009

    Article  CAS  Google Scholar 

  23. Akakura K, Suzuki H, Ueda T et al (2003) Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 56:106–109

    Article  CAS  Google Scholar 

  24. Ueda T, Bruchovsky N, Sadar MD (2002) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076–7085

    Article  CAS  Google Scholar 

  25. Komiya A, Shimbo M, Suzuki H et al (2010) Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol Lett 1:73–79

    Article  CAS  Google Scholar 

  26. Diederich S, Scholz T, Eigendorff E et al (2004) Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and gluco-corticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Horm Metab Res 36:423–429

    Article  CAS  Google Scholar 

  27. Nishimura K, Nonomura N, Yasunaga Y et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570–2576

    Article  CAS  Google Scholar 

  28. Lorente D, Omlin A, Ferraldeschi R et al (2014) Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 111:2248–2253

    Article  CAS  Google Scholar 

  29. Fenioux C, Louvet C, Charton E et al (2018) Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU Int

  30. Romero-Laorden N, Lozano R, Jayaram A et al (2018) Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer

  31. Roviello G, Petrioli R, Bonetta A et al (2018) Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. Invest New Drugs 2018

  32. Venkitaraman R, Lorente D, Murthy V et al (2015) A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67:673–679

    Article  CAS  Google Scholar 

  33. Sobhani N, Generali D, D’Angelo A et al (2018) Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest. New Drugs. https://doi.org/10.1007/s10637-018-0653-2

    Article  PubMed  Google Scholar 

  34. Gillessen S et al (2015) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589–1604

    Article  CAS  Google Scholar 

  35. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-linelong-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet 387:1163–1177

    Article  CAS  Google Scholar 

  36. Francini E, Petrioli R, Roviello G (2014) No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 14(10):1135–1140

    Article  CAS  Google Scholar 

  37. Petrioli R, Francini E, Roviello G (2015) Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 6(5):99–103

    Article  Google Scholar 

Download references

Funding

No Funding.

Author information

Authors and Affiliations

  1. Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy

    Giandomenico Roviello

  2. Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149, Trieste, Italy

    Navid Sobhani & Silvia Paola Corona

  3. Breast Cancer Unit, ASST Cremona, Viale Concordia 1, 26100, Cremona, Italy

    Navid Sobhani

  4. Department of Biology and Biochemistry, University of Bath, Bath, B2 7AY, UK

    Alberto D’Angelo

Authors
  1. Giandomenico Roviello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Navid Sobhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvia Paola Corona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto D’Angelo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giandomenico Roviello.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roviello, G., Sobhani, N., Corona, S.P. et al. Corticosteroid switch after progression on abiraterone acetate plus prednisone. Int J Clin Oncol 25, 240–246 (2020). https://doi.org/10.1007/s10147-019-01577-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-019-01577-w

Keywords

Search

Navigation